文献速递妇科

子宫平滑肌瘤发病机制中的细胞外基质:未来治疗的潜在靶点

Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics.
PubMed 文献 · Hum Reprod Update · 2018-01-01

本文综述了细胞外基质(ECM)在子宫平滑肌瘤发病机制中的作用,以及靶向ECM的现有和未来药物治疗。肌瘤以胶原、纤连蛋白、层粘连蛋白和蛋白聚糖升高为特征,ECM蓄积受生长因子、细胞因子、类固醇激素和微小RNA影响。作者提出ECM应被视为未来治疗的关键靶点,引入特异性抗纤维化药物可能有助于控制肌瘤生长及相关症状。

要点

  • 子宫平滑肌瘤以胶原、纤连蛋白、层粘连蛋白和蛋白聚糖水平升高为特征。
  • ECM蓄积受TGF-β、激活素A、PDGF、TNF-α、雌激素、孕激素及miR-29家族等调控。
  • 作者提出ECM应被视为未来治疗的关键靶点,特异性抗纤维化药物可能有助于控制肌瘤生长。

核心结论

  • ECM在肌瘤纤维化中起关键作用,应被视为未来治疗的重要靶点。
  • 引入特异性抗纤维化药物可能是控制异常肌瘤生长及相关临床症状的良好解决方案。

研究设计与样本

  • 综述,检索PubMed和Google Scholar截至2017年5月发表的英文原创论文、综述及书籍章节。

主要发现

  • 子宫平滑肌瘤以胶原、纤连蛋白、层粘连蛋白和蛋白聚糖水平升高为特征。
  • ECM可诱导机械转导过程,如激活整合素-Rho/p38 MAPK/ERK通路,导致参与发病机制的细胞反应及肌瘤细胞与ECM之间双向信号改变。
  • ECM蓄积受生长因子(TGF-β、激活素A和PDGF)、细胞因子(TNF-α)、类固醇激素(雌激素和孕激素)和微小RNA(miR-29家族、miR-200c和miR-93/106b)影响。
  • TGF-βs(1和3)和激活素A被认为在肌瘤过度ECM蓄积(纤维化)中起关键作用;肌瘤中ECM和肌成纤维细胞水平升高支持这些肿瘤的纤维化特征。
  • ECM可作为促纤维化生长因子的储库,通过增加其稳定性和延长信号持续时间增强其活性。

关键数值与推荐

  • 已研究的靶向ECM的药物包括GnRH激动剂(醋酸亮丙瑞林)、GnRH拮抗剂(醋酸西曲瑞克)、选择性孕激素受体调节剂(醋酸乌利司他和阿索立尼)、抗孕激素(米非司酮)及天然化合物如维生素D和白藜芦醇。

临床怎么用

  • 目前尚无药物被专门作为抗纤维化剂引入肌瘤治疗。
  • 作者提出,可根据抗纤维化化合物调节ECM组分及其受体、生长因子、细胞因子、类固醇激素及其相应受体和细胞内信号通路以及微小RNA的能力来引入这些化合物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uterine leiomyoma (also known as fibroid or myoma) is the most common benign tumor of the uterus found in women of reproductive age. It is not usually fatal but can produce serious clinical symptoms, including excessive uterine bleeding, pelvic pain or pressure, infertility and pregnancy complications. Due to lack of effective medical treatments surgery has been a definitive choice for the management of this tumor. OBJECTIVE AND RATIONALE: Extracellular matrix (ECM) accumulation and remodeling are thought to be crucial for fibrotic diseases such as uterine leiomyoma. Indeed, ECM plays important role in forming the bulk structure of leiomyoma, and the ECM-rich rigid structure within these tumors is thought to be a cause of abnormal bleeding and pelvic pain. Therefore, a better understanding of ECM accumulation and remodeling is critical for developing new therapeutics for uterine leiomyoma. SEARCH METHODS: PubMed and Google Scholar were searched for all original and review articles/book chapters related to ECM and medical treatments of uterine leiomyoma published in English until May 2017. OUTCOMES: This review discusses the involvement of ECM in leiomyoma pathogenesis as well as current and future medical treatments that target ECM directly or indirectly. Uterine leiomyoma is characterized by elevated levels of collagens, fibronectin, laminins and proteoglycans. They can induce the mechanotransduction process, such as activation of the integrin-Rho/p38 MAPK/ERK pathway, resulting in cellular responses that are involved in pathogenesis and altered bidirectional signaling between leiomyoma cells and the ECM. ECM accumulation is affected by growth factors (TGF-β, activin-A and PDGF), cytokines (TNF-α), steroid hormones (estrogen and progesterone) and microRNAs (miR-29 family, miR-200c and miR-93/106b). Among these, TGF-βs (1 and 3) and activin-A have been suggested as key players in the accumulation of excessive ECM (fibrosis) in leiomyoma. The presence of elevated levels of ECM and myofibroblasts in leiomyoma supports the fibrotic character of these tumors. Interestingly, ECM may serve as a reservoir of profibrotic growth factors and enhance their activity by increasing their stability and extending their duration of signaling. At present, several classes of compounds, including gonadotropin-releasing hormone (GnRH) agonist (leuprolide acetate), GnRH antagonist (cetrorelix acetate), selective progesterone receptor modulators (ulipristate acetate and asoprisnil), antiprogestin (mifepristone) and natural compounds like vitamin D and resveratrol have been studied as medical treatments that target ECM in uterine leiomyoma. WIDER IMPLICATIONS: Although several types of drugs (mostly antiproliferative agents) are available for leiomyoma treatment, none of them were introduced specifically as antifibrotic agents. In light of its critical role in the process of fibrosis in leiomyoma, we propose that ECM should be considered as a crucial target for future therapeutics. Thus, the introduction of drugs that are specifically antifibrotic could be a good solution to control abnormal leiomyoma growth and associated clinical symptoms. The antifibrotic compounds can be introduced based on their ability to regulate ECM components and their receptors, as well as growth factors, cytokines, steroid hormones and their corresponding receptors and intracellular signaling pathways, as well as microRNAs, involved in ECM production in leiomyoma.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Islam MS, Ciavattini A, Petraglia F, et al. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018. PMID: 29186429. doi:10.1093/humupd/dmx032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。